SeraNovo
- Biotech or pharma, therapeutic R&D
- CMO, CRO
Small Molecule and Protein Degrader Bioavailability Experts
SeraNovo's proprietary NanoGlass Technology is designed to enhancing bioavailability and offer simple manufacturing for small molecules and oral peptides. Our cutting-edge formulation technologies offer several key benefits,
- 1.5-3x bioavailability enhancements over competing technologies,
- 4-8 week formulation development,
- simple manufacturing processes.
Among SeraNovo's many collaborations in small molecules are partnerships with Johnson & Johnson and AstraZeneca. In the protein degrader space, we collaborate with Arvinas & J2H to enhance the bioavailability of even the most challenging active ingredients.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}